Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.69 (
botulinum neurotoxin
)
1,901
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
While the poisonous effects of
botulinum neurotoxin
(
BoNT
) have been recognized since antiquity, the overall actions and mechanisms of effects of
BoNT
have been elucidated primarily over the past several decades. The general utility of
BoNT
is described in the paper, but the focus is mainly on the approaches towards negating the toxic effects of
BoNT
, and on the projection of an engineered
BoNT
molecule serving as a Trojan Horse to deliver a therapeutic load for treatment of a host of medical disorders. The
BoNT
molecule is configured with a binding domain, a zinc-dependent protease with specificity primarily for vesicular proteins, and a translocation domain for delivery of the metalloprotease into the cytoplasm. The anti-toxin approaches for
BoNT
include the use of vaccines, antibodies, block of
BoNT
binding or translocation, inhibition of metalloprotease activity, impeded translocation of the protease/catalytic domain, and inhibition of the downstream Src signaling pathway. Projections of
BoNT
as a therapeutic include its targeting to non-cholinergic nerves, also targeting to non-neuronal cells for treatment of hypersecretory disorders (e.g.,
cystic fibrosis
), and treatment of hormonal disorders (e.g., acromegaly). Still in the exploratory phase, there is the expectation of major advances in
BoNT
neuroprotective strategies and burgeoning utility of engineered BoNTs as therapeutics.
...
PMID:Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. MiniReview. 2619 75
